211 related articles for article (PubMed ID: 37630410)
21. Preclinical investigations using [
Tschan VJ; Borgna F; Busslinger SD; Stirn M; Rodriguez JMM; Bernhardt P; Schibli R; Müller C
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3639-3650. PubMed ID: 35635566
[TBL] [Abstract][Full Text] [Related]
22.
Dai R; Cai Z; Hu R; Huang Y; Fu L; Yang J; Hu K; Li H
Mol Pharm; 2024 Feb; 21(2):883-894. PubMed ID: 38155100
[TBL] [Abstract][Full Text] [Related]
23. Albumin-Binding and Conventional PSMA Ligands in Combination with
Tschan VJ; Busslinger SD; Bernhardt P; Grundler PV; Zeevaart JR; Köster U; van der Meulen NP; Schibli R; Müller C
J Nucl Med; 2023 Oct; 64(10):1625-1631. PubMed ID: 37442604
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and Preclinical Evaluation of Urea-Based Prostate-Specific Membrane Antigen-Targeted Conjugates Labeled with
Machulkin AE; Petrov SA; Bodenko V; Larkina MS; Plotnikov E; Yuldasheva F; Tretyakova M; Bezverkhniaia E; Zyk NY; Stasyuk E; Zelchan R; Majouga AG; Tolmachev V; Orlova A; Beloglazkina EK; Yusubov MS
ACS Pharmacol Transl Sci; 2024 May; 7(5):1457-1473. PubMed ID: 38751647
[No Abstract] [Full Text] [Related]
25. Enhancing Treatment Efficacy of
Kuo HT; Merkens H; Zhang Z; Uribe CF; Lau J; Zhang C; Colpo N; Lin KS; Bénard F
Mol Pharm; 2018 Nov; 15(11):5183-5191. PubMed ID: 30251544
[TBL] [Abstract][Full Text] [Related]
26. Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.
Lim J; Guan B; Nham K; Hao G; Sun X; Simanek EE
Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31466360
[TBL] [Abstract][Full Text] [Related]
27.
Abouzayed A; Seitova K; Lundmark F; Bodenko V; Oroujeni M; Tolmachev V; Rosenström U; Orlova A
Front Oncol; 2023; 13():1221103. PubMed ID: 37829345
[TBL] [Abstract][Full Text] [Related]
28. Investigations Using Albumin Binders to Modify the Tissue Distribution Profile of Radiopharmaceuticals Exemplified with Folate Radioconjugates.
Busslinger SD; Becker AE; Vaccarin C; Deberle LM; Renz ML; Groehn V; Schibli R; Müller C
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686538
[TBL] [Abstract][Full Text] [Related]
29. Development of [
Wen X; Xu P; Zeng X; Liu J; Du C; Zeng X; Cheng X; Wang X; Liang Y; Zhao T; Yang H; Li H; Meng L; Fang J; Liu H; Zhou Z; Zhang J; Zhang X; Guo Z; Chen X
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2846-2860. PubMed ID: 37097443
[TBL] [Abstract][Full Text] [Related]
30. Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer.
Alati S; Singh R; Pomper MG; Rowe SP; Banerjee SR
Semin Nucl Med; 2023 Sep; 53(5):663-686. PubMed ID: 37468417
[TBL] [Abstract][Full Text] [Related]
31. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
32. Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403.
Ling X; Latoche JD; Choy CJ; Kurland BF; Laymon CM; Wu Y; Salamacha N; Shen D; Geruntho JJ; Rigatti LH; Windish HP; Langton-Webster B; Berkman CE; Anderson CJ
Mol Imaging Biol; 2020 Apr; 22(2):274-284. PubMed ID: 31321650
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and Preclinical Evaluation of
Wurzer A; Kunert JP; Fischer S; Felber V; Beck R; Rose F; D'Alessandria C; Weber W; Wester HJ
J Nucl Med; 2022 Oct; 63(10):1489-1495. PubMed ID: 35086894
[TBL] [Abstract][Full Text] [Related]
34. Preclinical Evaluation of a High-Affinity Sarcophagine-Containing PSMA Ligand for
Kelly JM; Ponnala S; Amor-Coarasa A; Zia NA; Nikolopoulou A; Williams C; Schlyer DJ; DiMagno SG; Donnelly PS; Babich JW
Mol Pharm; 2020 Jun; 17(6):1954-1962. PubMed ID: 32286841
[TBL] [Abstract][Full Text] [Related]
35. Preclinical dosimetric studies of
Meléndez-Alafort L; Ferro-Flores G; Santos-Cuevas C; Ocampo-García B; Turato S; Fracasso G; Bolzati C; Rosato A; De Nardo L
Med Phys; 2021 Jul; 48(7):4064-4074. PubMed ID: 33966284
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and evaluation of novel radioiodinated PSMA targeting ligands for potential radiotherapy of prostate cancer.
Yao X; Zha Z; Ploessl K; Choi SR; Zhao R; Alexoff D; Zhu L; Kung HF
Bioorg Med Chem; 2020 Mar; 28(5):115319. PubMed ID: 32001090
[TBL] [Abstract][Full Text] [Related]
37. Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer.
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Wüstemann T; Barelli P; Kim D; Williams C; Zheng X; Bi C; Hu B; Warren JD; Hage DS; DiMagno SG; Babich JW
J Nucl Med; 2017 Sep; 58(9):1442-1449. PubMed ID: 28450562
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of a Radio-IMmunoStimulant (RIMS) in a Syngeneic Model of Murine Prostate Cancer and ImmunoPET Analysis of T-cell Distribution.
Śmiłowicz D; Schlyer D; Boros E; Meimetis L
Mol Pharm; 2022 Sep; 19(9):3217-3227. PubMed ID: 35895995
[TBL] [Abstract][Full Text] [Related]
39. Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using
Yusufi N; Wurzer A; Herz M; D'Alessandria C; Feuerecker B; Weber W; Wester HJ; Nekolla S; Eiber M
J Nucl Med; 2021 Aug; 62(8):1106-1111. PubMed ID: 33443072
[TBL] [Abstract][Full Text] [Related]
40.
Lee BS; Chu SY; Jung WJ; Jeong HJ; Lee K; Kim MH; Kim MH; Chi DY; Ahn H; Lee YJ; Lee KC; Lim SM
Prostate; 2020 Dec; 80(16):1383-1393. PubMed ID: 32960990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]